MedTrace Logo

Interest of Reticulocyte Haemoglobin Content (RET-he) in Management of Functional Anemia for Patient With Solid Tumor

NCT03656172 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 54

Last updated 2021-04-21

No results posted yet for this study

Summary

Determine the value of the initial measurement of the hemoglobin content of reticulocytes (RET-He) for predicting the response to martial treatment for patients with a solid tumor with a functional martial deficiency as defined NCCN2016 (with or without inflammation). The aim is to refine the current definition of functional martial deficiency in order to best adapt the iron prescription in oncology by giving iron only if necessary, i.e. if the RET is low.

Conditions

  • Solid Tumor, Adult
  • Anemia Deficiency

Interventions

BIOLOGICAL

Haemoglobin measure

Haemoglobin measure before and one month after standard iron treatment

Sponsors & Collaborators

  • Institut Cancerologie de l'Ouest

    lead OTHER

Principal Investigators

  • Mathilde DUPE, MD · Institut de Cancérologie de l'Ouest

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-05-04
Primary Completion
2020-05-11
Completion
2020-05-11

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03656172 on ClinicalTrials.gov